<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145675</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-2016-2.24</org_study_id>
    <secondary_id>JS-1286</secondary_id>
    <nct_id>NCT03145675</nct_id>
  </id_info>
  <brief_title>Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)</brief_title>
  <acronym>OPTIENOX-PCI</acronym>
  <official_title>Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OPTIENOX-PCI is a randomized study, which is designed to assess the anticoagulation
      profile of different dose regimens of enoxaparin, i.e., 0.5 mg/kg, 0.75 mg/kg, and 0.5 mg/kg
      with additional 0.25 mg/kg, in about 120 patients who plan to undergo elective trans-radial
      coronary angiography with or without subsequent PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After eligible patients are randomized into Planned Staged-dose Group and Planned Single-dose
      Group, first-dose anticoagulation will be administered immediately. All patients in the
      Planned Staged-dose Group will receive enoxaparin 0.5 mg/kg at the beginning of coronary
      angiography and only those with definite indication for subsequent PCI will be given
      additional enoxaparin 0.25 mg/kg at the beginning of PCI; while, all patients in the Planned
      Single-dose Group will receive enoxaparin 0.75 mg/kg at the beginning of coronary angiography
      irrespective of their indication for subsequent PCI. Blood samples for the measurement of
      Anti-Xa activity will be obtained at 0 min (immediately before first-dose administration), 10
      min, 90 min, 180 min after first-dose administration in all patients. Additional blood
      samples for Anti-Xa assessment will be collected only in patients undergoing subsequent PCI
      immediately before and at 10 min after the beginning of PCI, as well as at the end of PCI.
      The primary objective of the present study is to obtain the values of Anti-Xa activity at the
      above time points in each group of patients. In patients who undergo subsequent PCI, the
      proportion of patients with therapeutic anticoagulation (Anti-Xa 0.5-1.8 IU/ml) at 10 min
      after the beginning of PCI and at 90 min after first-dose administration will be compared
      respectively between the two groups (Staged-dose PCI Group [0.5+0.25 mg/kg] versus
      Single-dose PCI Group [0.75 mg/kg]). In patients who do not undergo subsequent PCI, the
      proportion of patients with therapeutic anticoagulation at 10 min and 90 min after first-dose
      administration will be compared respectively between the two groups (High-dose Group [0.75
      mg/kg] versus Standard-dose Group [0.5 mg/kg]).

      In conclusion, the OPTIENOX-PCI study will 1) obtain the Anti-Xa activity of enoxaparin at
      each time point of sampling; 2) assess the anticoagulation profile of high- versus
      standard-dose enoxaparin (0.75 mg/kg vs. 0.5 mg/kg), as well as that of staged- versus
      single-administration of high-dose enoxaparin (0.5+0.25 mg/kg vs. 0.75 mg/kg). The result of
      the present study will provide pharmacodynamical data for the design of future outcome
      studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients are randomized into Planned Staged-dose Group and Planned Single-dose Group.
All patients in the Planned Staged-dose Group will receive enoxaparin 0.5 mg/kg at the beginning of coronary angiography. Those with definite indication for subsequent PCI will be given additional enoxaparin 0.25 mg/kg at the beginning of PCI (Staged-dose PCI Group [0.5+0.25 mg/kg]); while, those have no indication for subsequent PCI will not receive additional anticoagulation (Standard-dose Group [0.5 mg/kg]).
All patients in the Planned Single-dose Group will receive enoxaparin 0.75 mg/kg at the beginning of coronary angiography no matter they will undergo subsequent PCI (Single-dose PCI Group [0.75 mg/kg]) or not (High-dose Group [0.75 mg/kg]).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic anticoagulation (in patients NOT undergoing PCI, i.e., High-dose Group versus Standard-dose Group).</measure>
    <time_frame>At 10 min after first-dose administration in patients NOT undergoing PCI.</time_frame>
    <description>The proportion of patients with Anti-Xa 0.5-1.8 IU/ml (0.75 mg/kg versus 0.5 mg/kg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic anticoagulation (in patients undergoing PCI, i.e., Staged-dose PCI Group versus Single-dose PCI Group).</measure>
    <time_frame>At 10 min after the beginning of PCI (i.e., insertion of guiding catheter) in patients undergoing PCI.</time_frame>
    <description>The proportion of patients with Anti-Xa 0.5-1.8 IU/ml (0.5+0.25 mg/kg versus 0.75 mg/kg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic anticoagulation.</measure>
    <time_frame>At 90 min after first-dose administration.</time_frame>
    <description>The proportion of patients with Anti-Xa 0.5-1.8 IU/ml.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major adverse cardiac events (MACE).</measure>
    <time_frame>Up to 24 hours.</time_frame>
    <description>The proportion of patients with the composite of death, or myocardial infarction, or urgent coronary revascularization, or definite or probable stent thrombosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Thrombolysis in myocardial infarction (TIMI) major or minor bleeding.</measure>
    <time_frame>Up to 24 hours.</time_frame>
    <description>The proportion of patients with the composite of TIMI major or minor bleeding.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Enoxaparin (Staged-dose PCI Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and additional enoxaparin 0.25 mg/kg at the beginning of PCI (i.e., insertion of guiding catheter).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin (Single-dose PCI Group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and NO additional enoxaparin at the beginning of PCI (i.e., insertion of guiding catheter).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin (High-dose Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin (Standard-dose Group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin (Staged-dose PCI Group)</intervention_name>
    <description>Enoxaparin 0.5+0.25 mg/kg administered intravenously.</description>
    <arm_group_label>Enoxaparin (Staged-dose PCI Group)</arm_group_label>
    <other_name>Clexane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin (Single-dose PCI Group)</intervention_name>
    <description>Enoxaparin 0.75 mg/kg administered intravenously.</description>
    <arm_group_label>Enoxaparin (Single-dose PCI Group)</arm_group_label>
    <other_name>Clexane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin (High-dose Group)</intervention_name>
    <description>Enoxaparin 0.75 mg/kg administered intravenously.</description>
    <arm_group_label>Enoxaparin (High-dose Group)</arm_group_label>
    <other_name>Clexane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin (Standard-dose Group)</intervention_name>
    <description>Enoxaparin 0.5 mg/kg administered intravenously.</description>
    <arm_group_label>Enoxaparin (Standard-dose Group)</arm_group_label>
    <other_name>Clexane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of written informed consent.

          2. Aged 18 years or older, male or female.

          3. Documented stable coronary artery disease (SCAD) or non-ST-segment elevation acute
             coronary syndromes (NSTE-ACS).

          4. Plan to undergo elective trans-radial coronary angiography with or without subsequent
             PCI.

          5. No fibrinolytic, or anticoagulant, or parenteral antiplatelet therapy within 7 days of
             screening.

          6. Negative cardiac troponin test within 7 days of screening.

          7. Trans-radial approach successfully established.

          8. Females who are either post-menopausal &gt; 1 year or surgically sterile.

        Exclusion Criteria:

          1. Recent (within 30 days of screening) acute myocardial infarction, including ST-segment
             elevation myocardial infarction or non-ST-segment elevation myocardial infarction.

          2. The aim of the index coronary angiography is to undergo primary PCI or early PCI for
             acute coronary syndromes.

          3. Any indications other than coronary artery disease (e.g., atrial fibrillation,
             prosthetic heart valve, venous thromboembolism, ventricular thrombosis, et al) for
             fibrinolytic or anticoagulant treatment during study period.

          4. Planned use of any fibrinolytic or antithrombotic agents, with the exception of
             enoxaparin, aspirin, clopidogrel, and ticagrelor during study period.

          5. Planned coronary artery bypass graft (CABG) during study period.

          6. Increased bleeding risk, including

               -  any history of intracranial, intraocular, retroperitoneal, or spinal bleeding;

               -  recent (within 30 days of screening) gastrointestinal (GI) bleeding;

               -  recent (within 30 days of screening) major trauma or major surgery;

               -  planned surgery or other invasive procedure during study period;

               -  sustained uncontrolled hypertension (systolic blood pressure [SBP] &gt; 180 mmHg or
                  diastolic blood pressure [DBP] &gt; 100 mmHg) within 7 days of screening;

               -  history of hemorrhagic disorders, e.g., haemophilia, von Willebrand's disease;

               -  inability to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during
                  study period;

               -  platelet count less than 100,000/mm3 or hemoglobin &lt; 10 g/dL within 7 days of
                  screening.

          7. Contraindications for enoxaparin, e.g., hypersensitivity, active bleeding, bleeding
             diathesis, coagulation disorders, acute infectious endocarditis, thrombocytopenia
             (including heparin-induced thrombocytopenia), cerebral hemorrhage, severe liver of
             kidney diseases, severe hypertension, stroke, retinopathy, et al.

          8. History of intolerance to enoxaparin.

          9. Patient requires dialysis or has a creatinine clearance &lt; 30 mL/min as calculated by
             the Cockcroft-Gault equation: Clcr = (140 - Age) × WT / (72 × Scr) (× 0.85 for
             females), where WT is weight in kg, Scr is serum creatinine in mg/dL measured within 7
             days of screening.

         10. Any acute or chronic unstable conditions in the past 30 days which, in the opinion of
             the investigator, may either put the patient at risk or influence the result of the
             study, e.g., active cancer, et al.

         11. Any condition that may increase the risk of non-compliance to study protocol or
             follow-up, e.g., history of drug addiction or alcohol abuse, et al.

         12. Patients who has previously been randomized in this study.

         13. Participation in another investigational drug or device study within 30 days of
             screening.

         14. Involvement in the planning and conduct of the study (applies to investigators,
             contract research organization staff, and study site staff).

         15. Known pregnancy, breast-feeding, or intend to become pregnant during the study period.

         16. Any condition which in the opinion of the investigator would make it unsafe or
             unsuitable for the patient to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenyu Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenyu Liu, M.D.</last_name>
    <phone>+861069155068</phone>
    <email>pumch_lzy@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lihong Xu, B.N.</last_name>
    <phone>+861069155068</phone>
    <email>xulihong1990@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyu Liu, M.D.</last_name>
      <phone>+861069155068</phone>
      <email>pumch_lzy@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Lihong Xu, B.N.</last_name>
      <phone>+861069155068</phone>
      <email>xulihong1990@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Dec 23;130(25):2354-94. doi: 10.1161/CIR.0000000000000133. Epub 2014 Sep 23. Erratum in: Circulation. 2014 Dec 23;130(25):e431-2. Dosage error in article text.</citation>
    <PMID>25249586</PMID>
  </results_reference>
  <results_reference>
    <citation>Argenti D, Hoppensteadt D, Heald D, Jensen B, Fareed J. Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. Am J Ther. 2003 Jul-Aug;10(4):241-6.</citation>
    <PMID>12845386</PMID>
  </results_reference>
  <results_reference>
    <citation>Bernat I, Horak D, Stasek J, Mates M, Pesek J, Ostadal P, Hrabos V, Dusek J, Koza J, Sembera Z, Brtko M, Aschermann O, Smid M, Polansky P, Al Mawiri A, Vojacek J, Bis J, Costerousse O, Bertrand OF, Rokyta R. ST-segment elevation myocardial infarction treated by radial or femoral approach in a multicenter randomized clinical trial: the STEMI-RADIAL trial. J Am Coll Cardiol. 2014 Mar 18;63(10):964-72. doi: 10.1016/j.jacc.2013.08.1651. Epub 2013 Nov 21.</citation>
    <PMID>24211309</PMID>
  </results_reference>
  <results_reference>
    <citation>Caputo RP, Tremmel JA, Rao S, Gilchrist IC, Pyne C, Pancholy S, Frasier D, Gulati R, Skelding K, Bertrand O, Patel T. Transradial arterial access for coronary and peripheral procedures: executive summary by the Transradial Committee of the SCAI. Catheter Cardiovasc Interv. 2011 Nov 15;78(6):823-39. doi: 10.1002/ccd.23052. Epub 2011 May 4. Review.</citation>
    <PMID>21544927</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen WH, Lau CP, Lau YK, Ng W, Lee PY, Yu CM, Ma E. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol. 2002 Aug;14(8):439-42.</citation>
    <PMID>12147872</PMID>
  </results_reference>
  <results_reference>
    <citation>Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001 Feb 20;103(7):961-6.</citation>
    <PMID>11181470</PMID>
  </results_reference>
  <results_reference>
    <citation>Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002 Dec 4;40(11):1943-50.</citation>
    <PMID>12475453</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen M. The role of low-molecular-weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):55S-61S. Review.</citation>
    <PMID>12644342</PMID>
  </results_reference>
  <results_reference>
    <citation>Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001 Feb 6;103(5):658-63.</citation>
    <PMID>11156876</PMID>
  </results_reference>
  <results_reference>
    <citation>Feldman DN, Swaminathan RV, Kaltenbach LA, Baklanov DV, Kim LK, Wong SC, Minutello RM, Messenger JC, Moussa I, Garratt KN, Piana RN, Hillegass WB, Cohen MG, Gilchrist IC, Rao SV. Adoption of radial access and comparison of outcomes to femoral access in percutaneous coronary intervention: an updated report from the national cardiovascular data registry (2007-2012). Circulation. 2013 Jun 11;127(23):2295-306. doi: 10.1161/CIRCULATIONAHA.112.000536.</citation>
    <PMID>23753843</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994 Apr;23(5):1061-5.</citation>
    <PMID>8144768</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferrante G, Rao SV, Jüni P, Da Costa BR, Reimers B, Condorelli G, Anzuini A, Jolly SS, Bertrand OF, Krucoff MW, Windecker S, Valgimigli M. Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv. 2016 Jul 25;9(14):1419-34. doi: 10.1016/j.jcin.2016.04.014. Epub 2016 Jun 29.</citation>
    <PMID>27372195</PMID>
  </results_reference>
  <results_reference>
    <citation>Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316. Epub 2009 Mar 30.</citation>
    <PMID>19332455</PMID>
  </results_reference>
  <results_reference>
    <citation>Gurm HS, Hosman C, Share D, Moscucci M, Hansen BB; Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Comparative safety of vascular closure devices and manual closure among patients having percutaneous coronary intervention. Ann Intern Med. 2013 Nov 19;159(10):660-6. doi: 10.7326/0003-4819-159-10-201311190-00004.</citation>
    <PMID>24247671</PMID>
  </results_reference>
  <results_reference>
    <citation>Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S-203S.</citation>
    <PMID>15383472</PMID>
  </results_reference>
  <results_reference>
    <citation>Karrowni W, Vyas A, Giacomino B, Schweizer M, Blevins A, Girotra S, Horwitz PA. Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2013 Aug;6(8):814-23. doi: 10.1016/j.jcin.2013.04.010. Review.</citation>
    <PMID>23968700</PMID>
  </results_reference>
  <results_reference>
    <citation>Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, Barr L, Matthai W, Todd M, Broderick T, Rubinstein R, Fareed J, Santoian E, Neiderman A, Brodie B, Zidar J, Ferguson JJ, Cohen M; NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001 Apr;13(4):272-8.</citation>
    <PMID>11287711</PMID>
  </results_reference>
  <results_reference>
    <citation>Kerré S, Kustermans L, Vandendriessche T, Bosmans J, Haine SE, Miljoen H, Vrints CJ, Beutels P, Wouters K, Claeys MJ. Cost-effectiveness of contemporary vascular closure devices for the prevention of vascular complications after percutaneous coronary interventions in an all-comers PCI population. EuroIntervention. 2014 Jun;10(2):191-7. doi: 10.4244/EIJV10I2A32.</citation>
    <PMID>24952056</PMID>
  </results_reference>
  <results_reference>
    <citation>Khambatta S, Othman H, Seth M, Lalonde T, Rosman HS, Gurm HS, Mehta RH; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) Investigators. Association Of Bleeding Avoidance Strategies with age-related bleeding and In-hospital mortality in patients undergoing percutaneous coronary Interventions. Cardiovasc Revasc Med. 2016 Jun;17(4):233-40. doi: 10.1016/j.carrev.2016.02.014. Epub 2016 Feb 27.</citation>
    <PMID>26994504</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee MS, Applegate B, Rao SV, Kirtane AJ, Seto A, Stone GW. Minimizing femoral artery access complications during percutaneous coronary intervention: a comprehensive review. Catheter Cardiovasc Interv. 2014 Jul 1;84(1):62-9. doi: 10.1002/ccd.25435. Epub 2014 Mar 10. Review.</citation>
    <PMID>24677734</PMID>
  </results_reference>
  <results_reference>
    <citation>Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011 Dec 6;58(24):e44-122. doi: 10.1016/j.jacc.2011.08.007. Epub 2011 Nov 7.</citation>
    <PMID>22070834</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, Ozoux ML, Pensyl CE, Bigonzi F. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004 Feb;61(2):163-70.</citation>
    <PMID>14755805</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 Mar 8;356(10):1020-9. Epub 2007 Feb 12.</citation>
    <PMID>17296821</PMID>
  </results_reference>
  <results_reference>
    <citation>McGarry TF Jr, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR, Lester RM, Kreulen TH. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1992 Jun;123(6):1445-51.</citation>
    <PMID>1595522</PMID>
  </results_reference>
  <results_reference>
    <citation>Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004 Jul 27;110(4):392-8. Epub 2004 Jul 12.</citation>
    <PMID>15249498</PMID>
  </results_reference>
  <results_reference>
    <citation>Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006 Sep 7;355(10):1006-17.</citation>
    <PMID>16957147</PMID>
  </results_reference>
  <results_reference>
    <citation>Montalescot G, Cohen M, Salette G, Desmet WJ, Macaya C, Aylward PE, Steg PG, White HD, Gallo R, Steinhubl SR; STEEPLE Investigators. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J. 2008 Feb;29(4):462-71. doi: 10.1093/eurheartj/ehn008.</citation>
    <PMID>18276619</PMID>
  </results_reference>
  <results_reference>
    <citation>Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P, Combes X, Huber K, Pollack C Jr, Bénezet JF, Stibbe O, Filippi E, Teiger E, Cayla G, Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout M, Collet JP, Vicaut E; ATOLL Investigators. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet. 2011 Aug 20;378(9792):693-703. doi: 10.1016/S0140-6736(11)60876-3.</citation>
    <PMID>21856483</PMID>
  </results_reference>
  <results_reference>
    <citation>Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 1996 Feb 15;93(4):667-71.</citation>
    <PMID>8640994</PMID>
  </results_reference>
  <results_reference>
    <citation>Navarese EP, De Luca G, Castriota F, Kozinski M, Gurbel PA, Gibson CM, Andreotti F, Buffon A, Siller-Matula JM, Sukiennik A, De Servi S, Kubica J. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011 Oct;9(10):1902-15. doi: 10.1111/j.1538-7836.2011.04445.x.</citation>
    <PMID>21777368</PMID>
  </results_reference>
  <results_reference>
    <citation>Rao SV, Ou FS, Wang TY, Roe MT, Brindis R, Rumsfeld JS, Peterson ED. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2008 Aug;1(4):379-86. doi: 10.1016/j.jcin.2008.05.007.</citation>
    <PMID>19463333</PMID>
  </results_reference>
  <results_reference>
    <citation>Rao SV, Cohen MG, Kandzari DE, Bertrand OF, Gilchrist IC. The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. J Am Coll Cardiol. 2010 May 18;55(20):2187-95. doi: 10.1016/j.jacc.2010.01.039.</citation>
    <PMID>20466199</PMID>
  </results_reference>
  <results_reference>
    <citation>Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.</citation>
    <PMID>26320110</PMID>
  </results_reference>
  <results_reference>
    <citation>Sachdeva S, Saha S. Transradial approach to cardiovascular interventions: an update. Int J Angiol. 2014 Jun;23(2):77-84. doi: 10.1055/s-0034-1372243. Review.</citation>
    <PMID>25075159</PMID>
  </results_reference>
  <results_reference>
    <citation>Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26 Suppl 1:31-8. Review.</citation>
    <PMID>11011804</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanborn TA, Tomey MI, Mehran R, Généreux P, Witzenbichler B, Brener SJ, Kirtane AJ, McAndrew TC, Kornowski R, Dudek D, Nikolsky E, Stone GW. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2015 Feb 15;85(3):371-9. doi: 10.1002/ccd.25663. Epub 2014 Oct 28.</citation>
    <PMID>25179260</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol. 2005 Oct;60(4):364-73. Erratum in: Br J Clin Pharmacol. 2005 Oct;60(4):455.</citation>
    <PMID>16187968</PMID>
  </results_reference>
  <results_reference>
    <citation>Silvain J, Beygui F, Ankri A, Bellemain-Appaix A, Pena A, Barthelemy O, Cayla G, Gallois V, Galier S, Costagliola D, Collet JP, Montalescot G. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. J Am Coll Cardiol. 2010 Feb 16;55(7):617-25. doi: 10.1016/j.jacc.2009.08.077.</citation>
    <PMID>20170785</PMID>
  </results_reference>
  <results_reference>
    <citation>Silvain J, Beygui F, Barthélémy O, Pollack C Jr, Cohen M, Zeymer U, Huber K, Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012 Feb 3;344:e553. doi: 10.1136/bmj.e553. Review.</citation>
    <PMID>22306479</PMID>
  </results_reference>
  <results_reference>
    <citation>Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007 Mar 17;369(9565):907-19.</citation>
    <PMID>17368152</PMID>
  </results_reference>
  <results_reference>
    <citation>Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol. 1997 Jun;29(7):1474-82.</citation>
    <PMID>9180107</PMID>
  </results_reference>
  <results_reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24.</citation>
    <PMID>22922414</PMID>
  </results_reference>
  <results_reference>
    <citation>Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Williams KA, Levine G, Harrington RA, Tcheng JE. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003 Feb 5;41(3):386-93.</citation>
    <PMID>12575964</PMID>
  </results_reference>
  <results_reference>
    <citation>Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015 Jun 20;385(9986):2465-76. doi: 10.1016/S0140-6736(15)60292-6. Epub 2015 Mar 16.</citation>
    <PMID>25791214</PMID>
  </results_reference>
  <results_reference>
    <citation>Wimmer NJ, Secemsky EA, Mauri L, Roe MT, Saha-Chaudhuri P, Dai D, McCabe JM, Resnic FS, Gurm HS, Yeh RW. Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis. Circ Cardiovasc Interv. 2016 Apr;9(4):e003464. doi: 10.1161/CIRCINTERVENTIONS.115.003464.</citation>
    <PMID>27059685</PMID>
  </results_reference>
  <results_reference>
    <citation>Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29.</citation>
    <PMID>25173339</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>LiuZhenyu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>Enoxaparin</keyword>
  <keyword>Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

